Cagrilintide

InvestigationalMetabolic ResearchWeight & metabolic
5.8

Worth trying, BioHarmony verdict

BioHarmony score 5.8 out of 10

Cagrilintide (AM833) is a long-acting amylin receptor analogue that drove about 11.8 percent weight loss as monotherapy at 68 weeks in REDEFINE 1 per Garvey 2025, with no hypoglycemia and lower nausea than GLP-1 drugs, though its real role is the amylin half of CagriSema.

Read full report

What is Cagrilintide?

Cagrilintide (AM833) is a long-acting amylin receptor analogue that drove about 11.8 percent weight loss as monotherapy over 68 weeks in the Phase 3 REDEFINE 1 trial, per Garvey 2025. The single most important thing to understand is what it is not. It is not a GLP-1 drug. It works on a separate appetite pathway, which is exactly why it sits at a modest score on its own yet becomes far more interesting when combined with semaglutide. If you came here thinking cagrilintide is a cheaper Ozempic, that framing is wrong, and the rest of this report explains why.

From the BioHarmony report, reviewed Sep 8, 2026.

Saved on this device only.

How it is thought to work

Agonist at amylin receptors AMY1R and AMY3R in the hindbrain

Safety watch-outs

  • Severe or persistent vomiting or signs of dehydration: stop and seek care.
  • Severe upper abdominal pain that radiates to the back (possible pancreatitis): stop and seek care.
  • Worsening or spreading injection-site reaction with each dose (possible sensitization): stop.
  • Any product with no verified certificate of analysis: do not inject, since grey-market contamination risk is real.

Full risk profile in the BioHarmony report.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

No approved-label or study protocol is recorded for Cagrilintide yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (2)

Attributed viewpoints, separate from primary research.

Co-studied relationships

These entries name compounds evaluated together in a human study. They are not instructions to combine treatments.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalInvestigational
CompoundingCannot be used in compounding under US federal law

FDA states that cagrilintide is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under federal law.

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.